Advanced search
Publication Cover
Journal of Medical Economics Volume 15, 2012 - Issue 6
Submit an article Journal homepage
1,049
Views
16
CrossRef citations to date
0
Altmetric
Original Article

Economic outcomes of exenatide vs liraglutide in type 2 diabetes patients in the United States: results from a retrospective claims database analysis

Elise M. PelletierDepartment of Health Economics and Outcomes Research, IMS Health, Inc. Watertown, MAUSACorrespondence[email protected]
,
Manjiri PawaskarGlobal Health Outcomes, Eli Lilly and Company Indianapolis, INUSA
,
Paula J. SmithDepartment of Health Economics and Outcomes Research, IMS Health, Inc. Watertown, MAUSA
,
Jennie H. BestMedical Research and Development, Amylin Pharmaceuticals, Inc. San Diego, CAUSA
&
Richard H. ChapmanDepartment of Health Economics and Outcomes Research, IMS Health, Inc. Alexandria, VAUSA
Pages 1039-1050 | Accepted 19 Apr 2012, Published online: 24 May 2012

Citations (16)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Jennifer Cai, Yuexi Wang, Onur Baser, Lin Xie & Wing Chow. (2016) Comparative persistence and adherence with newer anti-hyperglycemic agents to treat patients with type 2 diabetes in the United States. Journal of Medical Economics 19:12, pages 1175-1186.
Read now
Ronan Roussel, Luc Martinez, Tom Vandebrouck, Habiba Douik, Patrick Emiel, Matthieu Guery, Barnaby Hunt & William J. Valentine. (2016) Evaluation of the long-term cost-effectiveness of liraglutide therapy for patients with type 2 diabetes in France. Journal of Medical Economics 19:2, pages 131-144.
Read now
Stephen S. Johnston, Hiep Nguyen, Katherine Cappell, James K. Nelson, Bong-Chul Chu & Iftekhar Kalsekar. (2015) Retrospective study comparing healthcare costs and utilization between commercially insured patients with type 2 diabetes mellitus who are newly initiating exenatide once weekly or liraglutide in the United States. Journal of Medical Economics 18:9, pages 666-677.
Read now

Articles from other publishers (13)

B. Guerci, B. Charbonnel, P. Gourdy, S. Hadjadj, H. Hanaire, M. Marre & B. Vergès. (2019) Efficacy and adherence of glucagon-like peptide-1 receptor agonist treatment in patients with type 2 diabetes mellitus in real-life settings. Diabetes & Metabolism 45:6, pages 528-535.
Crossref
Hiep Nguyen, Robert Dufour & Amanda Caldwell-Tarr. (2017) Glucagon-Like Peptide-1 Receptor Agonist (GLP-1RA) Therapy Adherence for Patients with Type 2 Diabetes in a Medicare Population. Advances in Therapy 34:3, pages 658-673.
Crossref
Victoria Divino, Mitch DeKoven, Farhad Ali Khan, Kristina S. Boye, Hélène Sapin & Kirsi Norrbacka. (2017) GLP-1 RA Treatment Patterns Among Type 2 Diabetes Patients in Five European Countries. Diabetes Therapy 8:1, pages 115-128.
Crossref
Jaime A. Davidson, Federico Perez Manghi, Maria Yu, Bruno Linetzky & Laura Fernández Landó. (2016) Efficacy and Safety of Dulaglutide in Hispanic/Latino Patients with Type 2 Diabetes in the Award Clinical Program. Endocrine Practice 22:12, pages 1406-1414.
Crossref
Maria Yu, Jin Xie, Laura Fernandez Lando, Samaneh Kabul & Ralph W. Swindle. (2016) Liraglutide Versus Exenatide Once Weekly: Persistence, Adherence, and Early Discontinuation. Clinical Therapeutics 38:1, pages 149-160.
Crossref
Bruce Wang, Joshua A. Roth, Hiep Nguyen, Eugene Felber, Wes Furnback & Louis P. Garrison. (2015) The Short-Term Cost-Effectiveness of Once-Daily Liraglutide Versus Once-Weekly Exenatide for the Treatment of Type 2 Diabetes Mellitus in the United States. PLOS ONE 10:4, pages e0121915.
Crossref
Antonio Pérez, Pedro Mezquita Raya, Antonio Ramírez de Arellano, Teresa Briones, Barnaby Hunt & William J. Valentine. (2015) Cost-Effectiveness Analysis of Incretin Therapy for Type 2 Diabetes in Spain: 1.8 mg Liraglutide Versus Sitagliptin. Diabetes Therapy 6:1, pages 61-74.
Crossref
Patrick M. Zueger, Neil M. Schultz & Todd A. Lee. (2014) Cost Effectiveness of Liraglutide in Type II Diabetes: A Systematic Review. PharmacoEconomics 32:11, pages 1079-1091.
Crossref
Stephen S. Johnston, Hiep Nguyen, Eugene Felber, Katherine Cappell, James K. Nelson, Bong-Chul Chu & Iftekhar Kalsekar. (2014) Retrospective Study of Adherence to Glucagon-like Peptide-1 Receptor Agonist Therapy in Patients with Type 2 Diabetes Mellitus in the United States. Advances in Therapy 31:11, pages 1119-1133.
Crossref
Andrew J. Krentz & Marcus Hompesch. (2014) Cardiovascular Safety of New Drugs for Diabetes: Getting the Balance Right?. Pharmaceutical Medicine 28:3, pages 109-117.
Crossref
Mitch DeKoven, Won Chan Lee, Jonathan Bouchard, Marjan Massoudi & Jakob Langer. (2014) Real-World Cost-Effectiveness: Lower Cost of Treating Patients to Glycemic Goal with Liraglutide versus Exenatide. Advances in Therapy 31:2, pages 202-216.
Crossref
Pedro Mezquita Raya, Antonio Pérez, Antonio Ramírez de Arellano, Teresa Briones, Barnaby Hunt & William J. Valentine. (2013) Incretin Therapy for Type 2 Diabetes in Spain: A Cost-Effectiveness Analysis of Liraglutide Versus Sitagliptin. Diabetes Therapy 4:2, pages 417-430.
Crossref
Neale D CohenRalph AudehmElaine PretoriusJoey KayeLeon H ChapmanStephen Colagiuri. (2013) The rationale for combining GLP‐1 receptor agonists with basal insulin. Medical Journal of Australia 199:4, pages 246-249.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.